Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 12
2014 144
2015 749
2016 967
2017 991
2018 1011
2019 1043
2020 1197
2021 1185
2022 1063
2023 929
2024 927
2025 485

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,036 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Gomez E, Gondouin A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Leger J, Kerjouan M, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Bejan-Angoulvant T, Cottin V, Marchand-Adam S; EVER-ILD investigators and the OrphaLung network. Mankikian J, et al. Eur Respir J. 2023 Jun 8;61(6):2202071. doi: 10.1183/13993003.02071-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37230499 Free article. Clinical Trial.
Use of rituximab in glomerulopathies.
Dias CB, Woronik V. Dias CB, et al. J Bras Nefrol. 2022 Apr-Jun;44(2):145-146. doi: 10.1590/2175-8239-JBN-2022-E004. J Bras Nefrol. 2022. PMID: 35201257 Free PMC article. No abstract available.
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puéchal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2. Ann Intern Med. 2020. PMID: 32479166 Clinical Trial.
(SUMO)-wrestling with rituximab.
Cragg MS. Cragg MS. Blood. 2022 May 5;139(18):2728-2730. doi: 10.1182/blood.2022015912. Blood. 2022. PMID: 35511190 Free article. No abstract available.
ALSUntangled #67: rituximab.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, Bromberg M, Carter GT, Crayle J, Cudkowicz M, Dimachkie M, Feldman EL, Glass J, Goslinga J, Heiman-Patterson T, Jhooty S, Lichtenstein R, Lund I, Mcdermott C, Pattee G, Pierce K, Ratner D, Salmon K, Wicks P, Bedlack R. Li X, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):544-547. doi: 10.1080/21678421.2022.2122845. Epub 2022 Sep 15. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36106861 Review.
9,036 results